Inotuzumab Ozogamicin
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Inotuzumab Ozogamicin |
| DrugBank ID | DB05889 |
| Brand Names (EU) | Besponsa |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.24% |
Approved Indication (EMA)
Besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | drug-induced osteoporosis | 98.24% | DL |
| 2 | HER2 positive breast carcinoma | 97.77% | DL |
| 3 | normal breast-like subtype of breast carcinoma | 96.79% | DL |
| 4 | progesterone-receptor positive breast cancer | 96.79% | DL |
| 5 | breast tumor luminal A or B | 96.75% | DL |
| 6 | progesterone-receptor negative breast cancer | 96.68% | DL |
| 7 | severe nonproliferative diabetic retinopathy | 92.05% | DL |
| 8 | primary release disorder of platelets | 91.51% | DL |
| 9 | pseudo-von Willebrand disease | 89.85% | DL |
| 10 | infectious bovine rhinotracheitis | 89.69% | DL |
| 11 | malignant catarrh | 89.69% | DL |
| 12 | kidney pelvis sarcomatoid transitional cell carcinoma | 89.55% | DL |
| 13 | infiltrating bladder urothelial carcinoma sarcomatoid variant | 89.35% | DL |
| 14 | prostatic urethra urothelial carcinoma | 89.34% | DL |
| 15 | renal pelvis papillary urothelial carcinoma | 89.00% | DL |
| 16 | Glanzmann thrombasthenia | 88.58% | DL |
| 17 | transitional cell carcinoma | 87.95% | DL |
| 18 | cytomegalovirus infection | 86.65% | DL |
| 19 | amenorrhea (disease) | 86.62% | DL |
| 20 | benign neoplasm of tongue | 85.39% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.